Racura Oncology

Why Invest

Updates

Announcements

Home

Inter

Racura Oncology InvestorHub

Race Oncology Investor Briefing Session - Isomer IP Webinar, September 18, 2025

Race Oncology is pleased to release an investor webinar video, where Race’s Executive Chair Dr Peter Smith, CEO and Managing Director Dr Daniel Tillett and VP of Research Prof Michael Kelso presented an  IP update, followed by an investor Q&A.

✅ Bisantrene found to consist of three photoisomers with different biological and anticancer activities, which rapidly interconvert upon exposure to visible light.

✅ Race has created a range of manufacturing and physical processes to only infuse the pure active (E,E)-bisantrene isomer into patients.

✅ Three patent applications filed including composition of matter covering (E,E)-bisantrene.

✅ Granting of these patents could protect (E,E)-bisantrene for 20 years.

✅ Composition of matter patents are the most valuable IP in the pharma industry as they cover the chemical structure of the active drug in any formulation or dosage form.